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Background: The Intermountain Cystic Fibrosis Pediatric Center utilizes ticarcillin–clavulanate 400 mg/kg/day divided every 6 h, (maximum
24 g/day). This dosing strategy is higher than the Cystic Fibrosis Foundation (CFF) recommendations and the Food and Drug Administration
(FDA) approved package labeling. The purpose is to determine the safety of this dosing regimen.
Methods: A retrospective study of pediatric cystic fibrosis (CF) patients admitted from January 1, 2005 to December 31, 2009 who received the
dosing regimen for at least 7 days. Baseline and follow-up laboratory parameters were recorded. Statistical analysis was performed.
Results: 127 patients met inclusion criteria. The mean (±SD) ticarcillin dose was 3.5 g (±2.16) every 6 h; while the mean (±SD) total ticarcillin
dose was 13.5 g (±6.5) per day. No significant differences occurred in liver function tests, white blood count, and platelet count from baseline.
Serum creatinine showed a statistically significant decrease from baseline.
Conclusions: Higher than FDA approved doses of ticarcillin–clavulanate may be safely used in the treatment of exacerbations in pediatric cystic
fibrosis patients.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Antibiotics; Cystic fibrosis; Pediatrics; Ticarcillin–clavulanate; Safety1. Background
Ticarcillin–clavulanate (Timentin®) is a combination semi-
synthetic beta-lactam antibiotic (ticarcillin) and beta-lactamase
inhibitor (clavulanate) for intravenous (IV) administration. It is
commonly used in the treatment of infections caused by
susceptible aerobic gram positive, aerobic gram negative (i.e.
Pseudomonas aeruginosa) and anaerobic bacteria [1]. The
Cystic Fibrosis Foundation (CFF) recommends that the empiric
treatment of pulmonary exacerbations should include two anti-
pseudomonal antibiotics with different mechanisms of action
(i.e. anti-pseudomonal beta-lactam plus aminoglycoside) to
reduce the chance of developing resistance [2].⁎ Corresponding author. 100 North Mario Capecchi Drive, Salt Lake City, UT
84113, United States. Tel.: +1 801 662 2641; fax: +1 801 662 2622.
E-mail address: Jeffery.zobell@imail.org (J.T. Zobell).
1569-1993/$ - see front matter © 2010 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2010.04.003The Intermountain Cystic Fibrosis Pediatric Center has utilized
ticarcillin–clavulanate (400 mg/kg/day divided every 6 h, up to a
maximum dose of 24 g/day of the ticarcillin component) as the
first line anti-pseudomonal agent in conjunction with tobramycin
(10–12 mg/kg/day) since 1994. Multiple reasons exist for
ticarcillin–clavulanate to serve as the first line agent:• 90% of P. aeruginosa isolates in 2009 were susceptible to
ticarcillin–clavulanate [3]
• Less risk association with new methicillin-resistant Staph-
ylococcus aureus (MRSA) infections versus ceftazidime
[4,5]
• High rates of serum sickness with piperacillin/tazobactam
[6,7]
• Less expensive than ceftazidime, piperacillin/tazobactam,
meropenem, aztreonam, and imipenem/cilistatin [8].d by Elsevier B.V. All rights reserved.
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been brought into question since it differs from the CFF
recommendations and the Food and Drug Administration
(FDA) approved package labeling.
• CFF dosing recommendation [9,10]
○ 400 mg/kg/day divided every 6 h, (max 12 g/day)
• Ticarcillin–clavulanate FDA approved package labeling [1]
○ Mild to moderate infections—200 mg/kg/day divided
every 6 h
○ Severe infections (patientsb60 kg)—300 mg/kg/day divided
every 4 h
○ Mild to moderate infections (patients N60 kg)—3 g every
6 h (maximum 12 g/day)
○ Severe infections (patients N60 kg)—3 g every 4 h (maxi-
mum 18 g/day).
Multiple dosing references and studies have been published
suggesting an alternative ticarcillin–clavulanate dosing strategy
is preferred in cystic fibrosis (CF) patients (Table 1). No severeTable 1
Summary of ticarcillin/clavulanate studies and dosing references.
Studies
Reference Ticarcillin–clavulanate dosing
(ticarcillin component)
Ervin and Bullock [11] 400 mg/kg/day
Nelson et al. [12] 400 mg/kg/day
Conway et al. [13] 2 groups:
1st: Mean 468 mg/kg/day (ran
2nd: Mean 586 mg/kg/day (ra
Horrevorts et al. [14] 600 mg/kg/day
Schaad et al. [15] 500 mg/kg/day
De Groot et al. [16] 120 mg/kg×1 dose
Dosing references
Nelson Textbook of Pediatrics 18th Edition [17] Ticarcillin/clavulanate dose fo
divided every 6 h (max 24 g/d
Red Book 29th Edition; 2009 Report of the
Committee on Infectious Diseases;
The American Academy of Pediatrics [18]
Severe Infections:
200–300 mg/kg/day in 4 divid
(max 12–24 g/day)
Lexi-Comp Pediatric Dosage Handbook [19] Severe infections: 400 mg/kg/
6 h (max 18–24 g/day)adverse events were reported in the published studies utilizing
alternative dosing strategies that differ from the FDA approved
dosing strategy. The main purpose of this study is to determine
the safety profile of a higher than FDA approved dosing
strategy by analyzing specific laboratory parameters.
2. Methods
This was a retrospective database study of de-identified
pediatric CF patients admitted from January 1, 2005 to
December 31, 2009 to Intermountain Primary Children's
Medical Center. To be included in the study, patients received
ticarcillin–clavulanate 400 mg/kg/day divided every 6 h (max-
imum 24 g/day of ticarcillin component) for at least 7 days, and
have recorded baseline and follow-up laboratory data (i.e.
serum creatinine, liver function tests, white blood count (WBC),
and platelet count). Follow-up laboratory data were drawn
N4 days after starting ticarcillin–clavulanate therapy. Patients
were excluded from the study if they received b7 days of
ticarcillin–clavulanate therapy, or did not have any follow-upstrategy Adverse effects
Prolongation of bleeding time in 1
patient who received 400 mg/kg/day
Mild eosinophilia of 6–7% occurred in
3 children who received 400 mg/kg/day
Alkaline phosphatase levels did not rise
3 children had transient elevations in
Aspartate Transferase (AST) (50–81 IU)
1 child had microscopic hematuria
Blood Urea Nitrogen (BUN) and serum
creatinine (SCr) levels remained within
normal limits
No rashes attributable to ticarcillin reported
ge 249–762 mg/kg/day)
nge 186–620 mg/kg/day)
Non-significant fall in absolute neutrophil
count (ANC) and platelet count in both groups
No changes in BUN, SCr, and electrolytes
were noted
No change in SCr
Slight urticaria occurred in 1 patient
No significant changes in BUN, creatinine,
urinalysis, or hematological parameters occurred
Transient 3 fold increases in transaminases
occurred in 2 patients in ticarcillin group
Alkaline phosphatase significantly decreased
in the ticarcillin group
None reported
r CF: 400 mg/kg/day
ay)
N/A
ed doses
N/A
day divided every N/A
Table 2
Summary of laboratory parameters, adverse effects, and microbiology.
Laboratory parameter Baseline
(mean±SD)
Follow-up
(mean±SD)
p-value
Serum creatinine
(g/dL)—all patients
0.55±0.18 0.47±0.19 p=0.001
Serum creatinine
(g/dL)—patients
receiving ≥12 g/day
0.65±0.17 0.59±0.17 p=0.012
ALT (median)—all 25 (5 to 257) 33 (6 to 320) p=NS
ALT (median)—patients
receiving ≥12 g/day
24 (5 to 257) 33 (6 to 320) p=NS
AST (median)—all 40.5 (18 to 429) 40 (14 to 232) p=NS
AST (median)—patients
receiving ≥12 g/day
40.5 (18 to 117) 40 (14 to 232) p=NS
WBC (median)—all 9.7 (2.6 to 48.4) 8.8 (3.1 to 60.9) p=NS
WBC—patients
receiving ≥12 g/day
9.3±4.3 8.3±4.6 p=NS
Platelets—all 292±105 274±123 p=NS
Platelets—patients
receiving ≥12 g/day
277±99 276±126 p=NS
Reported adverse effects
Adverse effects Number of patients
Hematuria and anaphylaxis 1
Acute elevation of liver function tests 1
Arthralgia 2
Rash 1
Microbiological effects—susceptibility data
Ticarcillin–clavulanate susceptibility rate for
Pseudomonas aeruginosa (2005–2009)
Year
82% 2005
80% 2006
88% 2007
92% 2008
90% 2009
Microbiological effects—emergence of resistant organisms
Organism Number of patients
Methicillin-resistant S. aureus (MRSA) 19 a
S. maltophilia 34 a
B. cepacia 0
a 6 of these patients cultured positive for both MRSA and S. maltophilia.
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WBC, or platelet counts). Other variables examined include
reported adverse reactions, susceptibility data, and culture
status. The data were analyzed using descriptive statistics and
Mann–Whitney U test (paired data with unequal variances)
[20].
3. Results
155 patients (age: 0–19 years; weight: 3.45–71.2 kg) received
ticarcillin–clavulanate 400 mg/kg/day from January 1, 2005 to
December 31, 2009. 127 patients with 276 unique encounters met
inclusion criteria. During this study time frame, 11,868 doses
were received. 12 patients received 6 g every 6 h; 1 patient
(68 kg) received 6.8 g every 6 h, and another (60 kg) patient
received 24 g over 24 h. The remaining 113 patients received
doses equaling 400 mg/kg/day up to 24 g of ticarcillin compo-
nent/day. The mean (±SD) ticarcillin dose was 3.5 g (±2.16)
every 6 h; while the mean (±SD) total ticarcillin dose was 13.5 g
(±6.5) per day. The mean (±SD) length of hospital stay was 13.1
(±6.5) days. The baseline and follow-up laboratory parameters,
reported adverse effects, and microbiological results are summa-
rized in Table 2. The safety parameters showed no statistically
significant differences from baseline (p=NS) except for serum
creatinine (for all patients and in those who received ≥12 g of
ticarcillin component/day). The serum creatinine values showed a
statistically significant decrease from 0.55 (±0.18) g/dL at
baseline to 0.47 (±0.19) g/dL at follow-up (pb0.05). Reported
adverse effects include arthralgias, rash, acute elevation of liver
function tests, hematuria, and anaphylaxis. The ticarcillin–
clavulanate susceptibility in P. aeruginosa isolates increased
during the course of the study (82% to 90%), and 53 patients
cultured positive for a new organism on cultures subsequent to a
course of ticarcillin–clavulanate.
4. Discussion
The purpose of performing this retrospective chart review
was to validate the safe use of higher than FDA approved doses
of ticarcillin–clavulanate in a pediatric CF population. The
Intermountain Cystic Fibrosis Pediatric Center has been using
ticarcillin–clavulanate as its first line anti-pseudomonal beta-
lactam, and the dosing strategy of 400 mg/kg/day divided every
6 h (maximum 24 g/day of ticarcillin component) for over
15 years. It was not until late 2009, that a discrepancy was noted
between pediatric, package insert, adult, and CFF dosing
regimens. These questions lead to an investigation into the basis
of the dosing recommendations in the standard dosing
references. An extensive literature search was performed that
lead to the discovery of several older studies showing the safe
and effective use of higher than approved doses of ticarcillin–
clavulanate in CF and non-CF patients (Table 1).
To our knowledge, this is the largest retrospective study
analyzing the safety of high dose ticarcillin–clavulanate in
pediatric CF patients. The mean doses of 3.5 g every 6 h,
maximum 13.5 g/day (ticarcillin component), are higher than
the FDA approved dose of 3 g every 6 h, maximum 12 g/day(ticarcillin component). Our results are consistent with the
dosage recommendations provided by De Groot and colleagues
[16]. The only safety parameter that showed a statistically
significant difference was serum creatinine. We felt that this
was clinically significant because these patients were receiving
high dose ticarcillin–clavulanate along with another known
nephrotoxic agent, intravenous tobramycin. Adverse reactions,
ranging from rash to anaphylaxis occurred in five patients who
received the study regimen. Although these reactions are listed
in the package insert, their true causality in this study cannot be
determined retrospectively.
Clinical efficacy parameters (susceptibility patterns of ticar-
cillin–clavulanate in P. aeruginosa, and the acquisition of new
organisms) were also examined. The susceptibility rate to
ticarcillin–clavulanate in P. aeruginosa improved from 2005 to
2009. 34% of participants cultured positive for a new organism.
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concern exists with the number of newly acquired cases of S.
maltophilia, since ticarcillin–clavulanate has been associated
with acquisition of this organism [9]. The causality of the
relationship between the microbiological results and high dose
ticarcillin–clavulanate also cannot be determined based on the
retrospective study design.
In addition to the causality limitations already mentioned,
another study limitation is that the only patients that were
included in the study were those who had follow-up laboratory
monitoring.
Based on the study results, we conclude ticarcillin–
clavulanate 400 mg/kg/day divided every 6 h (maximum 24 g
of ticarcillin component/day) appears to be safe and well-
tolerated by the majority of CF patients who receive it for
pulmonary exacerbations. More studies of this dosing regimen
are needed in order to fully answer the clinical effects (i.e.
clinical response rate) and causality of adverse reactions and
microbiological effects.Acknowledgements
The authors would like to thank Mark MacKay, BSPharm,
Clinical Manager, Intermountain Primary Children's Medical
Center and David C. Young, Pharm.D., Associate Professor of
Pharmacotherapy, University of Utah College of Pharmacy.References
[1] Timentin® Approved Package labeling. GlaxoSmithKline, 2009.
[2] Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn
RJ, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary
exacerbations. Am J Resp Crit Care Med 2009;180:802–8.
[3] Primary Children's Medical Center Microbiology Laboratory. Cumulative
Antimicrobial Susceptibility Test (Antibiogram) Data Report. 2010.[4] Crowcroft NS, Roveaux O, Monnet DI, Mertens R. Methicillin-resistant
Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect
Control Hosp Epidemiol 1999;20(1):31–6.
[5] Nadesalingam K, Conway SP, Denton M. Risk factors for acquisition of
methicillin-resistant Staphylococcus aureus (MRSA) by patients with
cystic fibrosis. J Cyst Fibros 2005;4(1):49–52.
[6] Moller NE, Hoiby N. Antibiotic treatment of chronic Pseudomonas
aeruginosa infection in cystic fibrosis patients. Scand J Infect Dis Suppl
1981;29:87–91.
[7] Reed MD, Stern RC, Myers CM, Klinger JD, Yamashita TS, Blumer JL.
Therapeutic evaluation of piperacillin for acute pulmonary exacerbations
in cystic fibrosis. Pediatr Pulmonol Mar–Apr 1987;3(2):101–9.
[8] Red Book, Thomson Healthcare; 2007 Ed.
[9] Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of
pulmonary infections in cystic fibrosis. Am J Resp Crit Care Med
2003;168:918–51.
[10] Microbiology and Infectious Disease in Cystic Fibrosis. Cystic Fibrosis
Foundation Consensus Conference. 1994; Volume V, Section I.
[11] Ervin FR, Bullock WE. Clinical and pharmacological studies of ticarcillin
in gram-negative infections. Antimicrob Agents Chemother 1976;9(1):
94–101.
[12] Nelson JD, Kusmiesz H, Shelton S,Woodman E. Clinical pharmacology and
efficacy of ticarcillin in infants and children. Pediatrics 1978;61:858–63.
[13] Conway SP, Miller MG, Ramsden C, Littlewood JM. Intensive treatment
of pseudomonas chest infection in cystic fibrosis: a comparison of
tobramycin and ticarcillin, and netilimicin and ticarcillin. Acta Paediatr
Scand 1985;74:107–13.
[14] Horrevorts AM, de Witte J, Degener JE, Dzoljic-Danilovic G, Hop WC,
Driessen O, et al. Tobramycin in patients with cystic fibrosis. Adjustment
in dosing interval for effective treatment. Chest 1987;92:844–8.
[15] Schaad UC, Desgrandchamps D, Kraemer R. Antimicrobial therapy of
pseudomonas pulmonary exacerbations in cystic fibrosis. Acta Paediatr
Scand 1986;75:128–38.
[16] De Groot R, Hack BD, Weber A, Chaffin D, Ramsey B, Smith AL.
Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a controlled
prospective study. Clin Pharmacol Ther 1990;47:73–8.
[17] Nelson Textbook of Pediatrics 18th Edition by Kliegman, Behrman,
Jenson, and Stanton; 2007, Elsevier, Inc. 1119, 1182.
[18] Red book 29th edition. Report of the Committee on Infectious Diseases.
The American Academy of Pediatrics; 2009.
[19] Pediatric dosage handbook. Lexi-Comp, Inc.; 2010.
[20] http://faculty.vassar.edu/lowry/utest.html.
